Review
Nature Reviews Cancer 5, 876-885 (November 2005) | doi:10.1038/nrc1736
There is a Corrigendum (1 December 2005) associated with this article.
Promoting apoptosis as a strategy for cancer drug discovery
Stephen W. Fesik1 About the author
Abstract
Apoptosis is deregulated in many cancers, making it difficult to kill tumours. Drugs that restore the normal apoptotic pathways have the potential for effectively treating cancers that depend on aberrations of the apoptotic pathway to stay alive. Apoptosis targets that are currently being explored for cancer drug discovery include the tumour-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, the BCL2 family of anti-apoptotic proteins, inhibitor of apoptosis (IAP) proteins and MDM2.
- View At a Glance
Author affiliations
-
Cancer Research, Abbott Laboratories, Department R460, Building AP10-LL, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA.
Email: stephen.fesik@abbott.com
Published online 20 October 2005
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Apoptosis and cancer: When BAX is TRAILing awayNature Medicine News and Views (01 Mar 2002)
RESEARCH
Hyperglycemia Enhances DNA Fragmentation After Transient Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism Original Article
See all 24 matches for Research